Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A protein in human eggs may reveal hidden damage

NCT ID NCT06788379

Diagnosis Sponsor: Vida Recoletas Sevilla Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are studying whether levels of a protein called CENP-V in human eggs can serve as a marker of damage caused by aging or by the freezing and thawing process used in fertility treatment. The study includes women of advanced maternal age and women whose eggs undergo vitrification and thawing. Only immature eggs that would otherwise be discarded are analyzed, so no eggs intended for a patient's treatment are used.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If CENP-V levels track egg damage, clinics could one day use it to flag which eggs are likely to survive freezing and thawing, helping patients and doctors make better decisions about fertility treatment.
What could go wrong
This is a laboratory study of discarded immature eggs, not a treatment, so it cannot improve anyone's fertility by itself. A marker that works in a lab dish may not predict outcomes reliably in real treatment cycles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The reference population will be constituted of patients and donors with immature oocytes(GV, MI), obtained after oocyte collection, and mature oocytes (MII) vitrified from patients who decide not to use them and are willing to donate them to research projects. Women willing to participate in this study will be previously informed and will have to sign the informed consent form of the study. The recruitment of patients will be performed in IVI RMA Seville clinic.

Ages

18 to 45 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Group of patients with advanced maternal age (AMA): patients aged 36-45 years with AMA etiology as the main factor of infertility undergoing controlled ovarian stimulation. * Group of patients with vitrification / thawing of their oocytes: patients between 18-45 years of age who underwent oocyte vitrification to later, in the study cycle, thaw their oocytes. In this group we contemplate two subgroups: * Patients with vitrified / thawed oocytes and AMA: between 36-45 years at the moment of oocytes vitrification. * Patients with vitrified / thawed oocytes and non-AMA: between 18-35 years at the moment of oocytes vitrification. * Group of control patients: patients and donors with normal etiology, aged 18-35 years, undergoing controlled ovarian stimulation and collection procedures. Exclusion Criteria: * Patients with pathologies affecting the oocyte quality (PCO, POI, endometriosis, oncology patients, etc.). * Patients/donors with oocyte cryopreserved by slow freezing technique.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advance maternal age are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advance maternal age Establish the amount of cenpv protein in human oocytes as A diagnostic tool against damage caused by ageing or by the procedure of vitrification of oocytes Vitrification and thawing

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Vida Recoletas Sevilla S.L.

    RECRUITING

    Seville, SEVILLA, 41009, Spain